BNET Industries

Market Cap:$1.4B
Last Fiscal Year Sales:$345.3M
  • Public
  • US
Dow Jones Description

We are one of the few fully integrated global biotechnology companies, with a breakthrough marketed product (Abraxane ® ), global ownership of our proprietary technology platform and clinical pipeline, dedicated nanoparticle manufacturing capabilities for worldwide supply integrated with seasoned in-house capabilities, including discovery, clinical drug development, regulatory and sales and marketing.

Vice Chairman, President & CEOLeon O. Moulder
Number of Employees 734
Contact Information

11755 Wilshire Blvd Ste 2000

Los Angeles, California 90025

www.abraxisbio....

(310) 883-1300

NAICS Code Medical Laboratories: 621511

Recent Events

  • BUYINS.NET: Market Maker Surveillance Report. Top 6 Abnormal Price Friction Stocks For June 2, 2009

    6/03/09 - Joint Venture / Alliance - View Story

  • Expression Pathology signs development agreement with Abraxis BioScience

    4/21/09 - Joint Venture / Alliance - View Story

News & Analysis

abraxis bioscience inc. - All News and Analysis

Additional Resources

Decision Makers

Name (plus bio) Position
David O'Toole CFO & Executive Vice President
David O. Toole Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
Bruce J. Wendel Executive. Vice President Corporate Development
Ed Geehr Executive Vice President Operations

Board of Directors

Name (plus bio) Position
Leon O. Moulder Vice Chairman, President & CEO
Patrick Shiong Chairman and CEO
David S. Chen Board of Directors
Kirk K. Calhoun Board of Directors
Leonard Shapiro Board of Directors
Maili Bergman Board of Directors
Stephen D. Nimer Board of Directors
Steven Hassen Board of Directors
Organization Position Status
Abraxis Biosciences, Inc. Vice Chairman, President & CEO Current
Organization Position Status
Abraxis Biosciences, Inc. Chairman and CEO Current

David O'Toole joined Abraxis in 2008 with more than 24 years of experience in financial consulting and international tax services to global companies, and particular expertise in the life sciences industry. Before joining the team at Abraxis BioScience, Mr. O'Toole was with Deloitte & Touche LLP for 16 years, last serving as Partner - Strategic Client Group. There he was responsible for providing solutions to issues facing the life sciences industry, including enterprise cost reduction, commercialization and distribution of drugs, human resources, Sarbanes Oxley compliance and international tax planning. Mr. O'Toole was also Deloitte's Life Science leader in the Pacific Southwest for the last two years, helping to build their industry eminence in the marketplace. Mr. O'Toole's international experience includes a two year assignment in Paris, France, during which he was a consultant to large and medium-sized multi-national companies with an emphasis on cross border operational and tax planning. He also had a two year assignment in Tokyo, Japan. Mr. O'Toole earned his bachelor of science degree in accounting from the University of Arizona. He is a member of the American Institute of Certified Public Accountants, the California Society of Certified Public Accountants, the California Healthcare Institute and the Southern California Biomedical Counsel.

Organization Position Status
Abraxis Biosciences, Inc. CFO & Executive Vice President Current
California Society of Certified Public Accountants Board of Directors Current
The University of Arizona Bachelor of Science Degree In Accounting Former
Organization Position Status
Abraxis Biosciences, Inc. Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer) Current
Organization Position Status
Abraxis Biosciences, Inc. Executive. Vice President Corporate Development Current
American Bioscience Inc. Executive Vice President, Corporate Development Current
APP Pharmaceuticals, Inc. Executive Vice President, Corp Dev Current
Bristol-Myers Squibb Company Vice President, Corporate Development International Medicines Former
APP Pharmaceuticals, Inc. Vice President of Corporate Development Former
IVAX Corporation Vice President, Business Development Former
Bristol-Myers Squibb Company In, House Counsel Former
SmithKline Beecham Corporation Former
Georgetown University Juris Doctorate degree Former
Georgetown Law School Jd Former
Cornell University BS Former
Organization Position Status
Abraxis Biosciences, Inc. Executive Vice President Operations Current

David S. Chen, Ph.D. has served as a director since the separation in November 2007. Dr. Chen previously served as a director of Old Abraxis from June 1998 to the date of the separation. Dr. Chen has been a senior executive vice president of China Development Industrial Bank since February 2004. Dr. Chen also served as president of China Trust Venture Capital Corporation from October 2001 to May 2004 and was the chairman of Cypac Investment Management Limited from 1998-2001. He served as chief executive officer of Central Investment Holdings Company from July 1996 to February 2000, and chief financial officer from May 1991 to February 1994. Dr. Chen holds a B.S. in agricultural economics from National Taiwan University, a M.B.A. from California State University at Long Beach and a Ph.D. in business administration from Nova University, Florida.

Organization Position Status
Abraxis Biosciences, Inc. Board of Directors Current
California State University M.B.A. Former
Organization Position Status
Aspreva Pharmaceuticals Corporation Chairman Current
Adams Respiratory Therapeutics, Inc. Chairman Current
Replidyne, Inc. Chairman Current
Abraxis Biosciences, Inc. Board of Directors Current
APP Pharmaceuticals, Inc. Board of Directors Current
Adams Laboratories, Inc. Board of Directors Current
Replidyne, Inc. Board of Directors Current
Response Genetics Board of Directors Current
Ernst & Young partner Former
Aspreva Pharmaceuticals Corporation Board of Directors Former
Adams Respiratory Therapeutics, Inc. Board of Directors Former
University of Southern California B.S. in Accounting Former
Organization Position Status
Shapco, Inc. CEO Current
APP Pharmaceuticals, Inc. Board of Directors Current
Kelly Pipe Div. President, Shapco Former
Shapco, Inc. President Former
Shapco, Inc. Founder Former
Organization Position Status
Abraxis Biosciences, Inc. Board of Directors Current

Dr. Nimer is Professor of Medicine and Professor of Pharmacology at Weill Medical College of Cornell University. He also serves as Chief of Hematology Service and Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering Cancer Center in New York City. Dr. Nimer is a member of many national professional organizations, including the American Society of Hematology, the American Society of Clinical Oncology, and the International Society for Stem Cell Research. He serves as a Reviewer for major medical journals, including the New England Journal of Medicine and the Journal of the American Medical Association (JAMA) among many others. He serves on numerous national and international Grant Review Committees and is a prominent invited speaker at conferences on his areas of expertise. He has authored or co-authored nearly 200 peer-reviewed papers, reviews, editorials and textbook chapters, primarily focused on issues concerning hematology and oncology

Organization Position Status
Memorial Sloan-Kettering Cancer Center Inc. Chief of Hematology Service Current
Memorial Hospital, Inc Attending Physician Current
The G&P Foundation for Cancer Research Chairman Current
Abraxis Biosciences, Inc. Board of Directors Current
Onconova Therapeutics, Inc Board of Directors Current
APP Pharmaceuticals, Inc. Board of Directors Current
American Association for Cancer Research, Inc. Board of Directors Current
Neostem, Inc. Board of Directors Current
American Society of Hematology Board of Directors Current
American Society of Clinical Oncology Board of Directors Current
American Society of Hematology Member Current
American College of Physicians Fellow Current
American Association for Cancer Research, Inc. Member Current
University of California, Los Angeles Former
Cancer Research Chairman Former
University of Chicago M.D. Former
Massachusetts, Inc. B.S. In Biology Former
Massachusetts Institute of Technology B.S. in Biology Former
University of Chicago Pritzker School of Medicine Degree Former
Organization Position Status
Abraxis Biosciences, Inc. Board of Directors Current
advertisement
     ABII $36.18 -1.41 (-3.75% )
Average Volume 27,916
Shares Outstanding 40.12M
Market Cap 1.5B
Year High 78.946
Year Low 35.25
Earnings Per Share N/A
P/E Ratio -
Dividend N/A
Yield N/A
advertisement